BL-B01D1 demonstrated encouraging efficacy, not only in EGFR-mutated NSCLC, but also in 42 NSCLC EGFR wild-type patients who progressed while on chemotherapy-IO (ORR 40.5%, DCR 95.5%) [98]. Here, EGFR is linked to non-small cell lung carcinoma.